City of Baltimore sues Biogen over allegedly paying PBMs to stave off Tecfidera generic competition

The city of Baltimore is suing Biogen over allegedly scheming with pharmacy benefit managers (PBMs) to stave off generic competition for its multiple sclerosis treatment, Tecfidera.